Nuveen Asset Management LLC lifted its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 10.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,492,301 shares of the biotechnology company's stock after purchasing an additional 138,054 shares during the period. Nuveen Asset Management LLC owned 1.04% of Aurinia Pharmaceuticals worth $13,401,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also bought and sold shares of the stock. SBI Securities Co. Ltd. bought a new stake in Aurinia Pharmaceuticals during the 4th quarter valued at about $25,000. Tower Research Capital LLC TRC grew its position in Aurinia Pharmaceuticals by 368.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock valued at $30,000 after buying an additional 2,635 shares during the period. Natixis bought a new stake in Aurinia Pharmaceuticals during the fourth quarter valued at approximately $49,000. Blue Trust Inc. boosted its position in shares of Aurinia Pharmaceuticals by 3,041.4% in the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock worth $57,000 after purchasing an additional 6,174 shares during the period. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth approximately $90,000. 36.83% of the stock is currently owned by hedge funds and other institutional investors.
Aurinia Pharmaceuticals Stock Down 1.6%
Aurinia Pharmaceuticals stock traded down $0.13 during midday trading on Friday, hitting $7.86. 1,381,130 shares of the company's stock were exchanged, compared to its average volume of 1,336,782. The company has a market cap of $1.06 billion, a PE ratio of -52.40 and a beta of 1.16. The firm has a 50-day moving average of $7.97 and a two-hundred day moving average of $8.26. Aurinia Pharmaceuticals Inc. has a 12 month low of $5.15 and a 12 month high of $10.67. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.08 by $0.08. The company had revenue of $62.47 million for the quarter, compared to analyst estimates of $61.06 million. Aurinia Pharmaceuticals had a negative net margin of 10.23% and a negative return on equity of 4.41%. As a group, analysts expect that Aurinia Pharmaceuticals Inc. will post 0.11 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Aurinia Pharmaceuticals news, COO Matthew Maxwell Donley sold 65,902 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $527,216.00. Following the completion of the transaction, the chief operating officer now owns 739,456 shares in the company, valued at approximately $5,915,648. This represents a 8.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Greg Keenan sold 8,305 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $8.23, for a total transaction of $68,350.15. Following the completion of the transaction, the insider now owns 153,484 shares of the company's stock, valued at $1,263,173.32. This represents a 5.13% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 343,898 shares of company stock worth $2,753,094. 12.20% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen raised shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, March 27th.
Get Our Latest Research Report on Aurinia Pharmaceuticals
About Aurinia Pharmaceuticals
(
Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
See Also
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
